RecruitingPhase 2NCT07074002

Proof of Concept Study on BP1.4979 Effect on Essential Tremor

A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of BP1.4979 in Adult Patients With Essential Tremor


Sponsor

Bioprojet

Enrollment

50 participants

Start Date

Sep 17, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to learn if drug BP1.4979 works to treat essential tremors in adults. It will also learn about the safety of drug BP1.4979. The main questions it aims to answer are: * Does the drug BP1.4979 reduce tremors in individuals with essential tremor? * Do participants have a good safety and tolerability of drug BP1.4979? Researchers will compare drug BP1.4979 to a placebo (a look-alike substance that contains no drug) to see if drug BP1.4979 works to treat essential tremors. Participants will: * Take the study drug (active or a placebo) twice daily over a 4-week period * Visit the clinic 5 times for health checkups and questionnaires completion over a period of approximately 7 to 10 weeks * Complete a diary weekly to assess the impact of essential tremor on daily life


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria4

  • Male or female ≥18-85 years old
  • Confirmed diagnosis of ET, characterized by meeting the following criteria: (a) the presence of a bilateral upper limb action tremor that occurs in isolation; (b) a minimum duration of 3 years; and (c) the tremor may or may not be present in other areas such as the voice, or lower limbs
  • ET characterized by a TETRAS-P score of at least 1.5 in either the forward posture, wing beating posture, or finger-to-nose movement of at least one upper extremity
  • Female patient: post-menopausal woman having at least 12 months of natural amenorrhea without any alternative medical cause, or woman of childbearing potential using a highly effective method of contraception for the duration of the trial and for 1 month after stopping the investigational medication

Exclusion Criteria7

  • Severe tremor, defined as patient with ET characterized by a TETRAS-P score of ≥ 3 in either the forward posture, wing beating posture, or finger-to-nose movement of at least one upper extremity, or tremor of trunk
  • Isolated head tremor not accompanied with tremor of any other body part
  • Medical history or clinical evidence of any other conditions, whether medical, neurological, or psychiatric, that could potentially explain or contribute to the presence of tremors
  • Patient who takes a medication which may induce tremor
  • Direct or indirect injury or trauma to the nervous system within 3 months before the onset of tremor
  • Concomitant treatment with more than three drugs to treat ET
  • Any prior procedures for the treatment of ET such as deep brain stimulation, brain lesioning, or magnetic resonance (MR)-guided procedures, including MR-guided focused ultrasound

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBP1.4979

Selective dopamine D3 partial agonist

DRUGPlacebo

Matching placebo of BP1.4979 tablet


Locations(14)

CHU Amiens-Picardie

Amiens, France

CHU Besançon

Besançon, France

Hospices Civils De Lyon Hôpital Neurologique Pierre Wertheimer

Bron, France

CHU de Clermont-Ferrand - Hôpital Gabriel Montpied

Clermont-Ferrand, France

CHU Henri Mondor

Créteil, France

CHU de Lille - Hôpital Roger SALENGRO

Lille, France

Centre Hospitalier Régional De Marseille - Hôpital de la Timone

Marseille, France

CHRU Nancy - Hôpital Central

Nancy, France

CHU de Nice - Hôpital Pasteur 2

Nice, France

CHU de Nîmes

Nîmes, France

CHU Poitiers

Poitiers, France

CHU Rennes - CHU Pontchaillou

Rennes, France

Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre

Strasbourg, France

CHU Purpan - Bâtiment Pierre Paul Riquet

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07074002


Related Trials